Keryx Pharma Of Japan Reports Final Stage Success For Kidney Drug
This article was originally published in PharmAsia News
Executive Summary
Japan’s Keryx Biopharmaceuticals said a Phase III trial of its Zerenex (ferric citrate) for treating kidney disease showed it worked as well as U.S.-based Genzyme’s RenaGel (sevelamer).